RSV nursing: bronchiolitis, nirsevimab, and NCLEX review

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants under 1 year of age and a significant cause of serious respiratory illness in elderly adults and immunocompromised patients. In the United States, most children have had RSV by age 2, and CDC estimates that before infant RSV antibodies became available it hospitalized 58,000–80,000 children under 5 each year. In adults, the burden falls mainly on those 75 and older and on adults 50–74 with chronic heart or lung disease, immunocompromise, or other high-risk conditions – the groups CDC now recommends for RSV vaccination. RSV usually starts circulating in the fall and peaks in winter in temperate climates, creating peak demand on pediatric inpatient units during this period.

For nurses, RSV matters because early recognition of respiratory distress – especially in young infants – and timely intervention with positioning, oxygen, and high-flow nasal cannula can prevent respiratory failure. This reference covers everything you need: pathophysiology, high-risk populations, age-specific presentation, nursing assessment, diagnostics, interventions, medications including the new nirsevimab prophylaxis, isolation precautions, complications, discharge education, and six NCLEX-style practice questions. Use this alongside the vital signs by age reference and the nursing lab values cheat sheet for full RSV patient management.

RSV at a glance

Pathophysiology

Viral structure and mechanism of infection

RSV is a member of the Pneumoviridae family and uses its two surface glycoproteins – the fusion (F) protein and the attachment (G) protein – to enter respiratory epithelial cells. The F protein mediates fusion of the viral envelope with the host cell membrane, enabling viral entry. Importantly, the prefusion conformation of the F protein is the primary target of the most effective neutralizing antibodies and is the basis for both nirsevimab (Beyfortus) and the newer RSV vaccines approved for adults.

Unlike influenza, RSV does not undergo major antigenic shift. Antigenic variation exists between the two major subtypes (RSV-A and RSV-B) and accumulates gradually within each subtype, but the change is far less dramatic than influenza’s annual drift. This is why a single-dose monoclonal antibody like nirsevimab can provide a full season of protection.

Bronchiolitis: the key pathological process

In infants and young children, RSV infects the bronchiolar epithelium – the smallest airways. The inflammatory response causes:

1. Epithelial cell necrosis and sloughing – the ciliated epithelium lining the bronchioles dies and sheds into the airway lumen
2. Peribronchiolar edema and lymphocytic infiltration – the surrounding tissue swells
3. Mucus hypersecretion – goblet cells produce excess mucus that mixes with sloughed debris
4. Mucus plugging and partial airway obstruction – plugs cause air trapping distal to the obstruction; complete plugs cause atelectasis
5. Air trapping – trapped air increases total lung volume, causes hyperinflation visible on chest X-ray, and produces the characteristic prolonged expiratory phase on auscultation
6. Ventilation/perfusion (V/Q) mismatch – lung units that are ventilated but not perfused (or perfused but not ventilated) impair gas exchange, driving hypoxemia

The infant airway is particularly vulnerable because the bronchiolar diameter is small – even modest edema produces disproportionate airflow resistance (airway resistance is inversely proportional to the fourth power of the radius, so halving the radius raises resistance 16-fold). This explains why bronchiolitis severity is age-dependent: the younger the infant, the smaller the airways, the greater the physiologic impact of the same degree of inflammation.

Bronchiolitis vs RSV pneumonia

Bronchiolitis is the classic RSV syndrome in infants under 2 years. It is a clinical diagnosis – diffuse inflammation of the small airways with air trapping and expiratory obstruction. Chest X-ray shows hyperinflation and peribronchial thickening.

RSV pneumonia involves extension of infection into the alveoli, producing consolidation similar to bacterial pneumonia. RSV pneumonia is more common in immunocompromised patients and elderly adults. In severe cases, alveolar damage can progress to acute respiratory distress syndrome – see the ARDS nursing reference for management of severe respiratory failure in this context.

Seasonal pattern

RSV follows predictable seasonal peaks: October–March in temperate Northern Hemisphere climates, with December through February representing the highest-risk weeks. The COVID-19 pandemic disrupted normal RSV seasonality – seasons became atypical in 2021–2022 with out-of-season surges. Since 2023, RSV seasonality has largely normalized.

Clinical presentation by age group

RSV produces a spectrum of illness that varies dramatically by age and underlying health status. Recognizing age-specific presentations is essential for nurses triaging patients during RSV season.

Key teaching point: Infants with RSV do not always look critically ill at first assessment. Work of breathing often worsens with activity (feeding, crying) and may be most pronounced immediately after feeding. Assess before and after feeds, and track trends rather than single-point observations.

Nursing assessment

Respiratory assessment priorities

Assessment of the RSV patient centers on work of breathing and oxygenation status. Perform a structured respiratory assessment at each encounter:

1. Respiratory rate – Compare against age-appropriate norms (see the vital signs by age reference). Tachypnea is often the earliest sign of respiratory distress in infants. Normal infant RR is 30–60/min; RR persistently above 60–70 in an infant is significant.

2. SpO2 – The AAP 2014 guideline states clinicians may choose not to give supplemental oxygen when SpO2 exceeds 90%, and may choose not to use continuous pulse oximetry in infants who are not on oxygen; follow your unit’s monitoring policy. Infants with hemodynamically significant CHD or chronic lung disease have individualized targets set by their care team – infants with cyanotic CHD may normally run well below 90%, so never apply a generic target to them. SpO2 may be artificially elevated in patients with poor peripheral perfusion – assess waveform quality.

3. Work of breathing signs – assess systematically:

• Nasal flaring – nares widen with each breath; indicates respiratory distress
• Intercostal retractions – skin pulls inward between ribs
• Subcostal retractions – skin pulls inward below the ribcage
• Supraclavicular/suprasternal retractions – indicate more severe distress
• Grunting – audible on expiration; infant is using glottic closure to generate positive end-expiratory pressure (PEEP) and maintain alveolar recruitment. Grunting is a sign of significant respiratory distress.
• Accessory muscle use – sternocleidomastoid, scalene muscle use indicates near-maximal effort
• Head bobbing in infants – the head nods forward with each inspiratory effort, indicating use of the sternocleidomastoid as an accessory muscle; sign of severe distress

4. Auscultation – Expiratory wheeze (from small airway obstruction), inspiratory crackles (from reopening of collapsed airways), prolonged expiratory phase. Breath sounds may be diminished in areas of significant mucus plugging or atelectasis.

5. Feeding tolerance – In infants, feeding is a respiratory stress test. Inability to sustain adequate oral intake indicates respiratory compromise severe enough to interfere with coordination of breathing and sucking/swallowing. Track intake as a percentage of normal feeds; oral intake below 50% of normal is a marker of clinical severity.

6. Hydration status – Assess anterior fontanelle (sunken = dehydration), skin turgor, mucous membrane moisture, urine output (wet diapers), and capillary refill. Tachypnea increases insensible losses while poor feeding decreases intake – dehydration develops quickly.

Red flags requiring immediate escalation

• Apnea (any episode in infant <2 months; recurrent or prolonged in older infants)
• SpO2 <90% on supplemental oxygen or any SpO2 <85%
• Grunting at rest
• Cyanosis
• Altered mental status or extreme lethargy
• Failure to respond to HFNC after 1–2 hours of trial

Diagnostic workup

RSV is primarily a clinical diagnosis in infants with classic bronchiolitis during RSV season. Laboratory and radiologic testing does not change management in most cases. Testing is used when the diagnosis is uncertain, when the patient is being admitted, or when cohorting RSV-positive patients together is logistically important for infection control.

RSV antigen detection test: Nasal swab (nasopharyngeal swab preferred for best sensitivity). Rapid antigen tests provide results in 15–30 minutes. Sensitivity is approximately 80–90% in young children (viral shedding is highest and most reliable in this group) but significantly lower in adults.

PCR (polymerase chain reaction): Higher sensitivity (>95%) across all age groups. Preferred for immunocompromised patients, elderly adults, and when clinical suspicion is high despite a negative antigen test. Multiplex respiratory viral panels can simultaneously test for influenza A/B, RSV, parainfluenza, adenovirus, human metapneumovirus, and SARS-CoV-2 – useful during co-circulation seasons.

Chest X-ray (CXR): Bronchiolitis produces characteristic findings: hyperinflation (flattened diaphragms, increased anterior-posterior diameter), peribronchial thickening (prominent bronchial markings), and patchy atelectasis. CXR is not routinely required for classic bronchiolitis in infants but is indicated when the diagnosis is uncertain, when the patient fails to improve as expected, or when secondary bacterial pneumonia is suspected. Consolidation suggests pneumonia superimposed on bronchiolitis. See the pneumonia nursing reference for pneumonia assessment and management when RSV leads to lower respiratory tract consolidation.

Laboratory studies: Check the nursing lab values cheat sheet for normal ranges. CBC may show lymphocytosis (viral pattern). Serum electrolytes and BUN/creatinine assess hydration status in patients with poor oral intake. Blood gas (ABG or VBG) is reserved for patients with significant respiratory distress or impending respiratory failure.

Nursing interventions

Positioning

Position infants and children with the head of bed elevated at 30–45 degrees to reduce diaphragmatic pressure from abdominal contents and optimize respiratory mechanics. In infants, use an infant seat or wedge positioning system.

Prone positioning is contraindicated in unsupervised infants due to sudden infant death syndrome (SIDS) risk. Prone positioning may be considered in intubated infants in the ICU setting under continuous monitoring, but this is a physician/advanced practice decision – never independently prone an unmonitored infant.

Oxygen therapy

Administer humidified supplemental oxygen when SpO2 is persistently below 90% (AAP 2014), or to the individualized target ordered for infants with CHD or chronic lung disease. Dry oxygen worsens mucous membrane dryness and increases secretion viscosity.

Oxygen delivery methods by severity:

• Low-flow nasal cannula (LFNC): Flow rates 0.1–2 L/min in infants; appropriate for mild hypoxemia
• Simple face mask or non-rebreather mask: When higher FiO2 needed and HFNC is not yet initiated
• High-flow nasal cannula (HFNC): First-line escalation for moderate-severe bronchiolitis

High-flow nasal cannula (HFNC)

HFNC delivers heated, humidified air/oxygen at weight-based flows, commonly 1–2 L/kg/min (the PARIS trial used 2 L/kg/min), via large-bore nasal cannula prongs. Mechanisms of benefit in bronchiolitis:

• Reduces nasopharyngeal dead space, improving CO2 washout
• Provides modest positive airway pressure (2–4 cmH2O), splinting open small airways
• Reduces work of breathing, allowing the infant to redirect effort to feeding

In the PARIS trial (Franklin 2018, 1,472 infants treated outside the ICU), HFNC cut escalation of care from 23% to 12%, with no difference in length of stay or duration of oxygen therapy, and 61% of infants who failed standard oxygen responded to rescue HFNC. The trial does not show that HFNC reduces intubation, and the AAP 2014 guideline made no recommendation on HFNC because no randomized trial had then been completed. Many units now use it when standard oxygen fails. Monitor for response at 1–2 hours; failure to improve or worsening clinical status after HFNC initiation should prompt escalation and physician notification.

Airway suctioning

Infants are obligate nose-breathers. Nasal secretions significantly worsen airway obstruction and feeding difficulty. Perform gentle nasopharyngeal suctioning before feeds and as needed:

• Use bulb syringe for mild secretions
• Nasopharyngeal catheter suction for copious or thick secretions
• Normal saline nasal drops (1–2 drops per nostril) can loosen secretions before suctioning
• Avoid deep suctioning – it stimulates the vagal reflex and can cause bradycardia and laryngospasm

Hydration and nutrition

Adequate hydration is essential – tachypnea increases insensible fluid losses while illness decreases intake.

• Oral/bottle/breast feeds: Support small, frequent feeds if the infant can tolerate. Limit individual feed duration (e.g., 20–30 minutes) to avoid fatiguing an already-stressed infant.
• Nasogastric tube (NGT) feeds: Insert NGT when oral intake falls below 50–75% of normal. NGT feeds avoid the respiratory stress of bottle feeding while maintaining enteral nutrition.
• IV fluids: Initiate when oral and NGT feeds are insufficient to maintain hydration, or when the infant is too distressed to safely accept any enteral intake. Use isotonic fluids; monitor closely for fluid overload in patients with CHD.
• Monitor urine output: Wet diapers every 4–6 hours is acceptable; a marked reduction in wet diapers over 8 hours indicates significant dehydration.

Fever management

• Acetaminophen: Safe from birth for fever ≥38°C; dose by weight every 4–6 hours
• Ibuprofen: Safe in children ≥6 months; avoid in infants <6 months
• Aspirin: CONTRAINDICATED in all children and adolescents <18 years – risk of Reye’s syndrome (acute hepatic failure and encephalopathy). This is a high-yield NCLEX concept. See the medication rights in nursing reference for additional safety checks.

RSV medications

Isolation precautions

RSV is transmitted via large respiratory droplets (generated by coughing and sneezing) and by direct and indirect contact with contaminated secretions. In infant secretions, RSV survives on countertops for up to 6 hours, on rubber gloves for up to 1.5 hours, and on skin for up to 20 minutes (Hall 1980) – making contact transmission via hands and fomites a primary route in healthcare settings.

CDC isolation guidance (Appendix A) lists Standard + Contact precautions for the duration of illness for RSV in infants, young children, and immunocompromised adults:

• Gown and gloves for all patient contact (contact precautions)
• Mask and eye protection according to Standard Precautions – whenever splashes or sprays of respiratory secretions are likely, such as during suctioning. Many hospitals add droplet precautions for all respiratory viral illness; follow your facility’s policy
• Dedicated equipment – stethoscope, thermometer, oximeter probe – stays in the room; do not share between patients
• Cohorting – when multiple RSV-confirmed patients are admitted simultaneously, cohort them in the same ward section to reduce cross-contamination to non-RSV patients and to allow efficient staffing

Hand hygiene

Alcohol-based hand rub (ABHR) is the preferred method – the AAP 2014 bronchiolitis guideline (Key Action Statement 11b) recommends alcohol-based rubs when caring for children with bronchiolitis, with soap and water when rub is unavailable. RSV is an enveloped virus that alcohol inactivates readily. Use soap and water when hands are visibly soiled. Perform hand hygiene:

• Before and after all patient contact
• Before and after glove removal
• After contact with potentially contaminated surfaces in the patient’s environment

Educate families on hand hygiene during their visits and emphasize that RSV spreads on unwashed hands – a caregiver touching their face after handling secretions can self-inoculate, and then spread the virus to the next person or surface they touch.

Isolation precautions should be maintained for the duration of the illness. RSV shedding can persist for 3–8 days in immunocompetent patients and for weeks in immunocompromised individuals.

Complications

Most healthy infants with RSV bronchiolitis recover fully within 1–2 weeks. Complications are more likely in high-risk populations and in infants who present with significant respiratory compromise.

Apnea – The most dangerous complication in young infants, particularly those born prematurely. Apnea may be the presenting sign of RSV in infants under 2–3 months. All infants under 2 months admitted with RSV require continuous cardiorespiratory monitoring. Apnea can precede respiratory failure and requires immediate assessment and response per institutional protocol.

Respiratory failure – Severe bronchiolitis or RSV pneumonia can progress to respiratory failure requiring intubation and mechanical ventilation. Risk factors for severe disease include age under 12 weeks, prematurity, hemodynamically significant CHD, chronic lung disease, and immunodeficiency (AAP 2014), plus failure to respond to HFNC. If a patient on HFNC develops worsening work of breathing, rising PaCO2, altered mental status, or persistent SpO2 below 90%, notify the physician immediately and prepare for possible intubation.

Secondary bacterial infections – Disrupted bronchiolar epithelium is susceptible to bacterial co-infection. Common secondary infections include otitis media (very common after RSV in infants – ask about ear pain, increased irritability), bacterial pneumonia (Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae), and – in severe or prolonged illness – sepsis. Monitor for new fever after initial improvement, purulent secretions, or hemodynamic changes. See the sepsis nursing reference for early sepsis recognition and the hour-1 bundle.

Dehydration – A direct complication of increased fluid losses from tachypnea combined with decreased oral intake. Can progress to acute kidney injury if prolonged.

Exacerbation of chronic conditions – RSV is a potent trigger for exacerbation of reactive airway disease and asthma in older children and adults. In adults with COPD or heart failure, RSV lower respiratory tract illness can precipitate acute decompensation. RSV is also recognized as a cause of acute respiratory distress syndrome in severely immunocompromised patients – see the ARDS nursing reference.

Long-term outcomes – RSV bronchiolitis in infancy is associated with increased rates of recurrent wheeze and asthma in early childhood. The causal relationship is debated – it is unclear whether severe RSV causes permanent airway changes or whether infants who develop severe bronchiolitis have pre-existing airway biology that predisposes them to both RSV severity and later atopic disease.

Discharge education

Discharge from inpatient RSV care requires that the infant or child demonstrates sustained SpO2 at or above 90% on room air (or their individualized baseline in CHD or chronic lung disease), adequate oral intake, and caregivers who are confident in home management and return precautions.

Return precautions – teach families to return immediately for:

• Breathing that looks harder than at discharge (nasal flaring, visible retractions)
• SpO2 below 90% on home monitor (if prescribed)
• Refusal to feed or intake less than half of normal for more than 8 hours
• Fewer than 4 wet diapers in 24 hours
• Any pause in breathing of 20 seconds or longer, or any shorter pause with color change or limpness (apnea)
• Color change – cyanosis around the lips or fingertips
• Extreme lethargy, difficulty waking, or unresponsiveness

Prevention education

• Nirsevimab (Beyfortus) or clesrovimab (Enflonsia): For eligible infants, ensure caregivers understand this is a single dose of a monoclonal antibody that gives ready-made protection, which works differently from a vaccine. It covers one season; only certain high-risk children need a second-season dose.
• Hand hygiene: One of the most effective everyday prevention measures, alongside infant RSV immunization. Thorough handwashing before handling the infant, especially after being in public spaces during RSV season.
• Avoid sick contacts: Keep infants – especially those under 3 months – away from people with cold symptoms during RSV season.
• Breastfeeding: Breast milk contains immunoglobulins (including RSV-specific IgA) that provide partial protection against severe RSV illness. Encourage continued breastfeeding throughout illness and after discharge.
• Avoid tobacco smoke exposure: Secondhand smoke exposure impairs mucociliary clearance and dramatically increases RSV severity risk.
• Childcare exposure: Large group childcare increases RSV exposure risk for infants. Families should discuss timing of childcare entry with their pediatrician.

NANDA-I nursing care plans for RSV bronchiolitis

The five care plans below address the priority nursing diagnoses in RSV bronchiolitis. Each is structured around the NANDA-I format: diagnosis label, etiology, defining characteristics, and RSV-specific interventions with rationale.

Care plan 1: Ineffective airway clearance

NANDA-I diagnosis: Ineffective airway clearance (Domain 11: Safety/protection, Class 2: Physical injury)

Related to: Mucus hypersecretion and bronchiolar inflammation caused by RSV-mediated epithelial necrosis, peribronchiolar edema, and accumulation of sloughed cellular debris within the airway lumen

As evidenced by: Audible expiratory wheeze, prolonged expiratory phase, tachypnea, nasal flaring, intercostal and subcostal retractions, SpO2 below target range, and inability to clear nasal secretions independently

Nursing interventions and rationale:

1. Position the infant with the head of bed elevated 30–45 degrees. Elevation reduces pressure from abdominal contents against the diaphragm and promotes downward drainage of secretions, improving functional residual capacity and reducing work of breathing in infants with air-trapped lungs.

2. Perform nasopharyngeal suctioning before feeds and as needed using a bulb syringe for mild secretions or a nasopharyngeal catheter for thick or copious secretions. Infants are obligate nose-breathers; nasal secretion clearance directly reduces upper airway resistance and improves tidal volume delivery. Suction before feeds to reduce the respiratory effort required for feeding coordination.

3. Instill 1–2 drops of normal saline per nostril 2–3 minutes before suctioning. Saline drops loosen viscous secretions and facilitate their removal, improving the efficacy of mechanical suctioning without traumatizing the nasal mucosa.

4. Avoid deep nasopharyngeal suctioning beyond the nasopharynx. Deep suctioning triggers the vagal reflex, causing bradycardia and potentially laryngospasm in young infants. Limit catheter depth to the nasopharynx and use gentle, intermittent suction.

5. Auscultate lung fields before and after each suctioning episode. Comparing pre- and post-suction breath sounds confirms whether secretion clearance has occurred and guides the frequency of subsequent suctioning. Document diminished or absent sounds in areas of possible mucus plugging or atelectasis.

6. Administer humidified supplemental oxygen via nasal cannula or HFNC as ordered; titrate to keep SpO2 at or above 90%, or to the individualized target ordered for infants with CHD or chronic lung disease. Humidification prevents drying of airway secretions, preserving mucociliary function and reducing secretion viscosity. HFNC provides modest positive airway pressure (2–4 cmH2O) that splints partially obstructed bronchioles open, improving airflow and facilitating secretion movement toward the upper airway.

7. Monitor respiratory rate, work of breathing signs (nasal flaring, retractions, grunting), and SpO2 continuously; reassess airway clearance effectiveness every 1–2 hours and after each intervention. RSV bronchiolitis follows a clinical course that often worsens over 24–48 hours before improving; trending assessment data identifies deterioration before it reaches a critical threshold.

8. Teach caregivers hand hygiene and the correct technique for bulb syringe suctioning before discharge. Home suctioning with a bulb syringe reduces nasal secretion burden and improves feeding tolerance. Caregiver competency in this skill is essential because nasal congestion persists for 1–2 weeks after hospital discharge.

Care plan 2: Impaired gas exchange

NANDA-I diagnosis: Impaired gas exchange (Domain 3: Elimination and exchange, Class 4: Respiratory function)

Related to: Ventilation/perfusion (V/Q) mismatch from air trapping distal to mucus plugs, atelectasis from complete airway obstruction, and alveolar hypoventilation in bronchiolar units with near-complete obstruction

As evidenced by: SpO2 persistently below 90% (or below an individualized target), tachypnea with respiratory rates persistently above age-appropriate norms, grunting (infant using glottic closure to generate auto-PEEP), altered mental status or lethargy, and hyperinflation on chest X-ray

Nursing interventions and rationale:

1. Initiate or prepare for high-flow nasal cannula (HFNC) therapy at 1–2 L/kg/min for infants with SpO2 below target on low-flow oxygen or with increasing work of breathing. HFNC reduces nasopharyngeal dead space, washes out CO2, and generates 2–4 cmH2O of airway pressure that keeps partially obstructed bronchioles open, directly addressing the V/Q mismatch driving hypoxemia.

2. Assess the patient’s response to HFNC at 1–2 hours after initiation, evaluating changes in respiratory rate, work of breathing, SpO2, and mental status. Many HFNC protocols use a 1–2-hour reassessment point; failure to improve or clinical worsening requires escalation to CPAP, bilevel ventilation, or intubation.

3. Obtain arterial or venous blood gas as ordered for patients with significant respiratory distress, altered mental status, or those who fail to respond to HFNC. Rising PaCO2 (hypercapnia) signals ventilatory failure – the infant’s respiratory muscles are exhausted and CO2 is accumulating. This finding, alongside SpO2 below 90% despite HFNC, is the physiologic trigger for intubation.

4. Monitor SpO2 continuously with a pulse oximeter; verify waveform quality at each assessment. Poor peripheral perfusion from increased work of breathing reduces peripheral pulsatility and can produce falsely elevated SpO2 readings. A plethysmographic waveform of poor quality indicates the reading is unreliable – reposition the probe or apply to an alternative site.

5. Maintain head-of-bed elevation at 30–45 degrees and avoid supine flat positioning. Diaphragm displacement by abdominal contents in flat supine position reduces functional residual capacity in infants, worsening atelectasis in already-compromised lung units.

6. Notify the physician immediately if SpO2 falls below 90% despite supplemental oxygen, PaCO2 rises above the patient’s baseline, grunting worsens or becomes continuous, or mental status deteriorates. These findings signal impending respiratory failure requiring urgent escalation of respiratory support.

7. Avoid excessive oxygen administration; titrate FiO2 to the minimum required to achieve target SpO2. In premature infants, hyperoxia carries risk of retinopathy of prematurity (ROP). In all patients, oxygen toxicity at sustained high FiO2 causes oxidative damage to lung parenchyma. Targeting the minimum effective FiO2 is evidence-based practice.

8. Document SpO2 trends over each shift, noting correlations between SpO2 dips and activity (feeding, suctioning, crying). RSV bronchiolitis characteristically causes desaturation events during increased metabolic demand; understanding the pattern allows proactive scheduling of suctioning before feeds and brief pre-oxygenation before procedures.

Care plan 3: Ineffective breathing pattern

NANDA-I diagnosis: Ineffective breathing pattern (Domain 4: Activity/rest, Class 4: Cardiovascular/pulmonary responses)

Related to: Small airway obstruction from RSV-mediated bronchiolar inflammation, mucus plugging, and air trapping producing expiratory flow limitation and increased work of breathing in the infant’s already-compliant chest wall

As evidenced by: Tachypnea (respiratory rate above age-appropriate norms), visible intercostal and subcostal retractions, use of accessory muscles (sternocleidomastoid), prolonged expiratory phase on auscultation, and inability to coordinate breathing with feeding

Nursing interventions and rationale:

1. Assess respiratory rate, depth, rhythm, and work of breathing signs at minimum every 1–2 hours and with any change in clinical status. Tachypnea is the earliest and most sensitive indicator of respiratory compromise in infants. Serial assessment identifies trends toward decompensation before SpO2 falls.

2. Administer supplemental oxygen as ordered; escalate delivery method (nasal cannula → HFNC) based on increasing work of breathing or SpO2 deterioration. HFNC reduces the effort required to breathe by splinting small airways open and reducing the dead space the infant must overcome with each breath. This mechanical unloading directly reduces retractions and respiratory rate in most infants with bronchiolitis.

3. Limit individual feed duration to 20–30 minutes and offer feeds in small, frequent intervals. Feeding requires simultaneous coordination of sucking, swallowing, and breathing – a task that exceeds the respiratory reserve of infants with moderate-severe bronchiolitis. Brief, frequent feeds reduce the cumulative respiratory load per feeding episode.

4. Insert a nasogastric tube (NGT) and initiate NGT feeds when oral intake falls below 50–75% of the infant’s normal feed volume. NGT feeds bypass the suck-swallow-breathe coordination required for oral feeding, eliminating a major source of respiratory stress while maintaining enteral nutrition. Avoiding IV fluids as the first-line nutritional escalation preserves the gut mucosal barrier and reduces the risks associated with intravenous access.

5. Assess for head bobbing in infants with tachypnea. Head bobbing – the head nodding forward with each inspiratory effort – indicates sternocleidomastoid use as a primary accessory muscle of inspiration, signaling severe respiratory distress that may precede decompensation. Notify the physician when head bobbing is present.

6. Ensure proper cannula sizing for HFNC: the prongs should fill approximately 50% of the nare diameter but should not occlude the nare completely. Prongs that are too small fail to generate adequate airway pressure; prongs that completely occlude the nares prevent egress of excess gas, causing unintended positive pressure and gastric distension.

7. Monitor for periods of apnea in infants younger than 2 months and all premature infants using continuous cardiorespiratory monitoring. RSV is a cause of apnea of infancy – the mechanism is believed to involve RSV-induced upper airway receptor stimulation triggering reflex apnea. Continuous cardiorespiratory monitoring ensures apnea is detected and responded to immediately.

8. Reassess breathing pattern 30–60 minutes after any intervention (position change, suctioning, oxygen adjustment, HFNC initiation). Documenting the response to each intervention creates an evidence trail for clinical decision-making and allows timely identification of non-responders who require escalation.

Care plan 4: Risk for imbalanced fluid volume

NANDA-I diagnosis: Risk for imbalanced fluid volume (deficit) (Domain 2: Nutrition, Class 5: Hydration)

Risk factors: Increased insensible fluid losses from sustained tachypnea (each breath above the normal rate increases evaporative respiratory water loss), fever-related fluid losses, and decreased oral intake secondary to fatigue from increased work of breathing and poor suck-swallow-breathe coordination

Nursing interventions and rationale:

1. Track fluid intake and output at minimum every 4–8 hours; assess wet diapers as the primary urine output measure in infants. A wet diaper roughly every 4–6 hours (at least four in 24 hours) reflects adequate renal perfusion. A marked decrease in wet diapers over 8 hours in a tachypneic infant with poor oral intake indicates progressive dehydration before serum electrolyte changes occur.

2. Assess hydration status at each encounter: anterior fontanelle fullness/depression, mucous membrane moisture, skin turgor, capillary refill time, and recent feeding volume. Sunken anterior fontanelle, dry mucous membranes, tenting skin turgor, and capillary refill greater than 2–3 seconds are clinical signs of dehydration that precede laboratory abnormalities.

3. Escalate nutritional support in a stepwise manner: oral feeds → NGT feeds → IV fluids. Enteral feeding is preferred because it preserves gut mucosal integrity and is physiologically more appropriate than IV hydration in a hemodynamically stable infant. Initiate NGT feeds when oral intake falls below 50–75% of normal rather than defaulting immediately to IV fluids.

4. When IV fluids are required, use isotonic fluids (0.9% normal saline or Lactated Ringer’s) as the primary fluid type. Hypotonic IV fluids carry the risk of iatrogenic hyponatremia, particularly in infants with concurrent antidiuretic hormone (ADH) release from respiratory distress. Isotonic fluids avoid this risk.

5. Monitor serum electrolytes and blood urea nitrogen/creatinine as ordered. Serum sodium detects early hyponatremia or hypernatremia. BUN elevation disproportionate to creatinine elevation signals prerenal azotemia – a sign of inadequate renal perfusion from volume depletion.

6. Maintain strict fluid intake and output balance in infants with congenital heart disease (CHD). Infants with CHD are at high risk of fluid overload – even modest excess can precipitate pulmonary edema in those with left-to-right shunts. Fluid management in this population requires close collaboration with cardiology.

7. Monitor urine-specific gravity when available. Urine specific gravity above 1.020 in the setting of decreased output suggests concentrated urine from ADH-mediated water conservation, indicating fluid deficit. Specific gravity below 1.005 in the setting of adequate output confirms adequate hydration.

8. Provide discharge teaching on hydration monitoring: wet diaper count, fontanelle appearance, feeding volume, and the threshold for returning to the emergency department. Dehydration is a common cause of bounce-back admissions in RSV bronchiolitis. Caregivers who understand early dehydration signs can seek care before dehydration becomes severe.

Care plan 5: Deficient knowledge (caregiver)

NANDA-I diagnosis: Deficient knowledge (Domain 5: Perception/cognition, Class 4: Cognition)

Related to: Lack of prior exposure to RSV illness and its management, complexity of discharge instructions, and the stress of acute hospitalization impairing information processing and retention

As evidenced by: Caregiver verbalizes incorrect understanding of nirsevimab or clesrovimab as treatment for active RSV infection, caregiver unable to identify return-precaution warning signs, and caregiver expresses uncertainty about home suctioning technique or isolation measures at home

Nursing interventions and rationale:

1. Assess caregiver health literacy and prior knowledge about RSV before beginning teaching; tailor language and content to the individual. Baseline assessment prevents teaching content the caregiver already knows and identifies knowledge gaps that need the most attention. Use plain language, avoiding clinical jargon; check for understanding using the teach-back method.

2. Teach that infant RSV antibodies (nirsevimab or clesrovimab) are prophylaxis – not treatment – for RSV. Caregivers commonly believe prophylactic monoclonal antibodies will treat RSV if their infant becomes infected. This misconception is dangerous: caregivers may delay seeking care, believing their infant is protected. Reinforce that these antibodies reduce the risk of severe illness but cannot stop an infection that has already started.

3. Provide explicit return-precaution education with specific thresholds: (a) breathing that looks harder than at discharge with visible skin pulling between ribs; (b) SpO2 below 90% on a home monitor if prescribed; (c) intake less than half of normal for more than 8 hours; (d) fewer than 4 wet diapers in 24 hours; (e) any pause in breathing of 20 seconds or longer, or a shorter pause with color change; (f) blue color around the lips or fingernails. Use teach-back to confirm understanding. Specific, observable thresholds are more actionable than general statements like “if the baby looks worse.”

4. Explain the aspirin contraindication in children under 18 years. Aspirin is widely available over the counter; many caregivers are unaware that it is contraindicated in pediatric viral illnesses. Reye’s syndrome – characterized by acute hepatic failure and encephalopathy – has been associated with aspirin use during RSV and influenza illness. Advise caregivers to use acetaminophen or ibuprofen (if the infant is ≥6 months) for fever management.

5. Demonstrate and return-demonstrate bulb syringe nasal suctioning technique before discharge. Nasal congestion persists for 1–2 weeks post-discharge. Skill demonstration followed by caregiver return-demonstration is more effective than verbal or written instruction alone. The goal is caregiver confidence, not just compliance.

6. Teach RSV prevention measures: hand hygiene (alcohol-based hand rub or soap and water; soap and water when hands are visibly dirty), avoiding contact with anyone who has cold symptoms, keeping the infant away from large group settings during RSV season, and continuing breastfeeding if established. Prevention education reduces re-admission risk and protects younger siblings. Alcohol-based sanitizer inactivates RSV, so families can use whichever is at hand.

7. Explain the RSV seasonal pattern (fall and winter; immunization October–March in most of the US) and that only certain high-risk children receive nirsevimab again in their second season. Infant antibodies protect for one season. Caregivers of children with chronic lung disease of prematurity, severe immunocompromise, qualifying cystic fibrosis, or American Indian/Alaska Native heritage should plan a second-season dose with their pediatrician.

8. Coordinate with social work or case management if caregiver barriers to follow-up exist (transportation, language, housing instability, or lack of a primary care provider). Social determinants of health significantly affect the likelihood of successful home management and follow-up. Early identification and linkage to resources before discharge reduces preventable readmissions.

FAQ

What are the priority nursing interventions for RSV bronchiolitis?

The priority interventions are maintaining a patent airway, optimizing oxygenation, and supporting hydration. This means positioning the infant at 30–45 degrees, performing gentle nasopharyngeal suctioning before feeds, administering humidified supplemental oxygen when SpO2 stays below 90% (or below an individualized target for infants with heart or lung disease), and escalating to HFNC at 1–2 L/kg/min for infants who do not maintain adequate oxygenation on low-flow oxygen or who have increasing work of breathing. Tracking feeding volume as a percentage of normal intake is equally critical – oral intake below 50–75% of normal triggers NGT feeds.

Why are bronchodilators not recommended for RSV bronchiolitis?

The American Academy of Pediatrics (AAP) guidelines do not recommend bronchodilators (albuterol or epinephrine) for bronchiolitis because the primary pathology is inflammation, mucus plugging, and airway edema rather than bronchospasm. Bronchodilators act on smooth muscle, which is not the rate-limiting anatomical problem in bronchiolitis. Randomized trials and systematic reviews show that albuterol and racemic epinephrine do not reduce hospitalization, length of stay, or time to recovery in bronchiolitis. The 2014 AAP guideline dropped the trial-dose option that its 2006 version allowed, because no reliable way exists to identify which infants will respond.

What is the difference between nirsevimab and palivizumab?

Both are monoclonal antibodies targeting the RSV fusion (F) protein and are used for prophylaxis – not treatment – of RSV illness. Nirsevimab (Beyfortus), FDA approved in 2023, targets the prefusion F protein and protects for a full season with a single IM dose. CDC recommends it for infants under 8 months in their first RSV season unless the mother received the RSV vaccine at least 14 days before birth, and for certain high-risk children 8–19 months in their second season. Clesrovimab (Enflonsia, 2025) is a single-dose alternative for the first season. Palivizumab (Synagis), the older agent, required monthly IM injections (up to 5 per season) and is no longer available in the US after December 31, 2025. Neither drug treats active RSV infection – a common caregiver misconception that must be addressed during discharge education.

When should a nurse escalate an RSV patient from HFNC to intubation?

Escalation from HFNC should be considered when the patient fails to improve or worsens within 1–2 hours of HFNC initiation. Specific triggers include: SpO2 below 90% despite HFNC at maximum flow, rising PaCO2 on blood gas (indicating ventilatory failure), worsening or continuous grunting at rest, new or worsening altered mental status, recurrent apnea despite HFNC, or clinical judgment that the infant’s respiratory muscle fatigue is progressing toward collapse. The nurse’s role is to notify the physician immediately when these signs appear and to prepare for intubation: gather equipment, prepare medications, position the patient, and call respiratory therapy. Do not wait for the patient to arrest.

What isolation precautions are required for RSV?

CDC isolation guidance lists Standard plus Contact precautions for the duration of illness in infants, young children, and immunocompromised adults with RSV. Contact precautions mean gown and gloves for all patient contact, because RSV in infant secretions survives on countertops for up to 6 hours and on skin for up to 20 minutes, so hands and fomites drive much healthcare-associated spread. Under Standard Precautions, wear a mask and eye protection when splashes of secretions are likely, such as during suctioning; many hospitals also add droplet precautions for respiratory viruses, so follow facility policy. Dedicate equipment (stethoscope, thermometer, pulse oximeter probe) to the room. Alcohol-based hand rub is the preferred hand hygiene method (AAP 2014), with soap and water when hands are visibly soiled.

Why is aspirin contraindicated in children with RSV?

Aspirin is contraindicated in all children and adolescents under 18 years with viral illness due to the risk of Reye’s syndrome – a rare but potentially fatal condition characterized by acute hepatic failure and non-inflammatory encephalopathy. The association between aspirin use during viral illness (RSV and influenza in particular) and Reye’s syndrome was established in epidemiologic studies in the 1980s; widespread public health education led to a dramatic decline in Reye’s syndrome cases following reduced pediatric aspirin use. This is a high-yield NCLEX concept. Acetaminophen is safe from birth; ibuprofen is safe in children 6 months and older. Neither carries Reye’s syndrome risk.

What are the red flags for RSV in young infants that require immediate escalation?

In infants under 2–3 months (and particularly those born prematurely), apnea is the most urgent red flag – a pause in breathing of 20 seconds or longer, or a shorter pause accompanied by bradycardia, color change, or pallor, requires immediate response. Additional immediate escalation triggers include: SpO2 below 90% on supplemental oxygen, cyanosis (blue discoloration of the lips or nail beds), continuous grunting at rest (indicating severe air trapping), extreme lethargy or unresponsiveness, and failure to respond to HFNC after a 1–2-hour trial. Infants under 2 months with confirmed or suspected RSV require continuous cardiorespiratory monitoring because apnea can occur without other preceding warning signs.

How does RSV severity differ between premature and term infants?

Premature infants face two compounding vulnerabilities that increase RSV severity. First, their bronchioles are smaller than those of term infants – because airway resistance is inversely proportional to the fourth power of the airway radius, even modest bronchiolar inflammation produces far greater flow obstruction in a 32-week infant than in a 40-week infant. Second, the majority of transplacental IgG transfer occurs in the third trimester (32–40 weeks); infants born before this window receive significantly less passive maternal RSV-specific antibody protection. This leaves premature infants with both structurally compromised airways and reduced passive immunity simultaneously. Oxygen targets for infants with chronic lung disease of prematurity or congenital heart disease are set individually by the care team rather than taken from the general 90% threshold.

NCLEX practice questions

Summary

RSV is a seasonal respiratory virus that causes the spectrum of illness from mild URI in healthy adults to life-threatening bronchiolitis and respiratory failure in high-risk infants. Nursing priorities are respiratory assessment (work of breathing, SpO2, feeding tolerance), timely escalation to HFNC for moderate-severe bronchiolitis, and prevention of nosocomial spread via Standard plus Contact precautions. Maternal vaccination or a single-dose infant antibody (nirsevimab or clesrovimab) now protects most infants through their first season. For NCLEX, remember: bronchodilators and steroids are not standard care for bronchiolitis, aspirin is contraindicated under age 18, and nirsevimab, clesrovimab, and the retired palivizumab are prophylaxis – not treatment. Compare RSV to other respiratory viruses in the influenza nursing reference and the COVID-19 nursing reference.

References

1. Ralston, S.L., Lieberthal, A.S., Meissner, H.C., et al., “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis,” Pediatrics, 2014;134(5):e1474–e1502 (erratum Pediatrics 2015;136(4):782). doi:10.1542/peds.2014-2742
2. Griffiths, C., Drews, S.J., & Marchant, D.J., “Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment,” Clinical Microbiology Reviews, 2017;30(1):277–319. doi:10.1128/CMR.00010-16
3. Centers for Disease Control and Prevention, “RSV in Infants and Young Children,” cdc.gov, accessed October 8, 2026.
4. Centers for Disease Control and Prevention, “Clinical Guidance for RSV Vaccines for Adults” (adults 75 and older, and adults 50–74 at increased risk), updated August 18, 2025.
5. Jones, J.M., Fleming-Dutra, K.E., Prill, M.M., et al., “Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023,” MMWR, 2023;72(34):920–925. doi:10.15585/mmwr.mm7234a4
6. U.S. Food and Drug Administration, Prescribing Information – Nirsevimab-alip (Beyfortus), 2023.
7. U.S. Food and Drug Administration, Prescribing Information – Palivizumab (Synagis).
8. U.S. Food and Drug Administration, Prescribing Information – Ribavirin for inhalation solution (Virazole).
9. Franklin, D., Babl, F.E., Schlapbach, L.J., et al., “A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis” (PARIS trial), New England Journal of Medicine, 2018;378(12):1121–1131. doi:10.1056/NEJMoa1714855
10. Hall, C.B., Douglas, R.G., & Geiman, J.M., “Possible Transmission by Fomites of Respiratory Syncytial Virus,” The Journal of Infectious Diseases, 1980;141(1):98–102. doi:10.1093/infdis/141.1.98
11. American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, “Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection,” Pediatrics, 2014;134(2):415–420. doi:10.1542/peds.2014-1665
12. Centers for Disease Control and Prevention, “Clinical Overview of RSV,” CDC RSV Clinical Guidance, accessed October 8, 2026.
13. Domachowske, J.B., Anderson, E.J., & Goldstein, M., “The Future of Respiratory Syncytial Virus Disease Prevention and Treatment,” Infectious Diseases and Therapy, 2021;10(Suppl 1):47–60. doi:10.1007/s40121-020-00383-6
14. Hall, C.B., “Respiratory Syncytial Virus and Parainfluenza Virus,” New England Journal of Medicine, 2001;344(25):1917–1928. doi:10.1056/NEJM200106213442507
15. Piedimonte, G., & Perez, M.K., “Respiratory Syncytial Virus Infection and Bronchiolitis,” Pediatrics in Review, 2014;35(12):519–530. doi:10.1542/pir.35-12-519
16. Fleming-Dutra, K.E., Jones, J.M., Roper, L.E., et al., “Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023,” MMWR, 2023;72(41):1115–1122. doi:10.15585/mmwr.mm7241e1
17. Moulia, D.L., Link-Gelles, R., Chu, H.Y., et al., “Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices – United States, 2025,” MMWR, 2025;74(32):508–514. doi:10.15585/mmwr.mm7432a3
18. Centers for Disease Control and Prevention, “Clinical Guidance for RSV Immunization of Infants and Young Children” (nirsevimab and clesrovimab eligibility, dosing, timing; palivizumab no longer available from December 31, 2025), updated August 18, 2025.
19. Siegel, J.D., Rhinehart, E., Jackson, M., Chiarello, L., & HICPAC, “2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings,” Appendix A: Type and Duration of Precautions Recommended for Selected Infections and Conditions, CDC.
20. American Academy of Pediatrics Committee on Fetus and Newborn, “Apnea, Sudden Infant Death Syndrome, and Home Monitoring,” Pediatrics, 2003;111(4):914–917. doi:10.1542/peds.111.4.914
21. Sullivan, J.E., Farrar, H.C., AAP Section on Clinical Pharmacology and Therapeutics, & Committee on Drugs, “Fever and Antipyretic Use in Children,” Pediatrics, 2011;127(3):580–587. doi:10.1542/peds.2010-3852